MX2023011065A - Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. - Google Patents

Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.

Info

Publication number
MX2023011065A
MX2023011065A MX2023011065A MX2023011065A MX2023011065A MX 2023011065 A MX2023011065 A MX 2023011065A MX 2023011065 A MX2023011065 A MX 2023011065A MX 2023011065 A MX2023011065 A MX 2023011065A MX 2023011065 A MX2023011065 A MX 2023011065A
Authority
MX
Mexico
Prior art keywords
bicyclic heteroaryl
inhibitors
ectonucleotide pyrophosphatase
compounds
heteroaryl derivatives
Prior art date
Application number
MX2023011065A
Other languages
English (en)
Inventor
Klaus Klumpp
Ronald Hawley
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of MX2023011065A publication Critical patent/MX2023011065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona ciertos compuestos heteroarílicos bicíclicos que inhiben la actividad enzimática de la ectonucleótido pirofosfatasa/fosfodiesterasa 1 (ENPP1) y que son, por consiguiente, útiles para el tratamiento de enfermedades y afecciones moduladas al menos en parte por ENPP1. En algunas realizaciones, los compuestos heteroarílicos bicíclicos incluyen los de Fórmula (I): (ver Fórmula) (I) En la presente también se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
MX2023011065A 2019-04-12 2021-10-07 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. MX2023011065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833455P 2019-04-12 2019-04-12
US201962881111P 2019-07-31 2019-07-31

Publications (1)

Publication Number Publication Date
MX2023011065A true MX2023011065A (es) 2023-09-28

Family

ID=70465561

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012305A MX2021012305A (es) 2019-04-12 2020-04-10 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
MX2023011065A MX2023011065A (es) 2019-04-12 2021-10-07 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021012305A MX2021012305A (es) 2019-04-12 2020-04-10 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.

Country Status (23)

Country Link
US (1) US12029744B2 (es)
EP (2) EP3952995B1 (es)
JP (1) JP2022526432A (es)
KR (1) KR20210151873A (es)
CN (1) CN114040915A (es)
AU (1) AU2020272034A1 (es)
BR (1) BR112021020241A2 (es)
CA (1) CA3136443A1 (es)
DK (1) DK3952995T3 (es)
ES (1) ES2960987T3 (es)
FI (1) FI3952995T3 (es)
HR (1) HRP20231413T1 (es)
HU (1) HUE064377T2 (es)
IL (1) IL286966A (es)
LT (1) LT3952995T (es)
MX (2) MX2021012305A (es)
PL (1) PL3952995T3 (es)
PT (1) PT3952995T (es)
RS (1) RS64792B1 (es)
SG (1) SG11202110888QA (es)
SI (1) SI3952995T1 (es)
TW (1) TW202103708A (es)
WO (1) WO2020210649A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200318A1 (en) * 2020-10-30 2022-05-05 1Cbio, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
MX2023008761A (es) * 2021-01-29 2023-08-22 Txinno Bioscience Inc Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.
US20240209005A1 (en) * 2021-03-16 2024-06-27 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途
US20240208997A1 (en) * 2022-11-09 2024-06-27 Boehringer Ingelheim International Gmbh Cyclic benzimidazole derivatives as cgas inhibitors
WO2024149239A1 (zh) * 2023-01-10 2024-07-18 上海翊维康医药有限责任公司 杂芳环化合物及其制备方法和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5240938A (en) 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
IE914572A1 (en) 1991-01-17 1992-07-29 Zeneca Ltd Chemical process
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
WO2001044257A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
US20090264384A1 (en) 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
DE102004060699A1 (de) 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
EP1833801B9 (en) 2004-12-22 2009-02-25 Algry Quimica, S.L Intermediate compounds for the preparation of angiotensin ii receptor antagonists
ITMI20050801A1 (it) 2005-05-03 2006-11-04 Dipharma Spa Procedimento per la preparazione di telmisartan
US20090176849A1 (en) 2005-05-24 2009-07-09 Lek Pharmaceuticals, D.D. Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CN100427488C (zh) 2005-10-21 2008-10-22 上海东升新材料有限公司 腺嘌呤类衍生物及其合成方法
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
TWI399377B (zh) 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體７之調節劑
JP2009242240A (ja) 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
CA2705921A1 (en) 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivatives and their use as antihypertensive agents
EP3246034A1 (en) * 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
CA2724077C (en) 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
WO2010009029A2 (en) 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2011053247A1 (en) 2009-10-29 2011-05-05 Agency For Science, Technology And Research Method for the detection of an analyte by surface enhanced raman spectroscopy (sers)
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
DK2558577T3 (en) * 2010-04-16 2019-04-01 Nuevolution As Bi-functional complexes and methods for the preparation and use of such complexes
EP2670733B1 (en) 2011-02-01 2019-04-10 The Board of Trustees of the University of Illionis N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
AU2012255792A1 (en) * 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
SG11201401244TA (en) 2011-11-09 2014-09-26 Janssen R & D Ireland Purine derivatives for the treatment of viral infections
ES2611504T3 (es) 2012-03-07 2017-05-09 Institute Of Cancer Research: Royal Cancer Hospital (The) Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos
CR20160512A (es) 2014-05-01 2016-12-21 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7
WO2016036887A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Fluorescence assay for intestinal permeability
CA2963772A1 (en) 2014-10-08 2016-04-14 Thomas Helledays Stiftelse For Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
WO2016200840A1 (en) 2015-06-08 2016-12-15 Cleave Biosciences, Inc. Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex
JP6832914B2 (ja) * 2015-07-31 2021-02-24 ファイザー・インク Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
EP3478672B1 (en) 2016-06-29 2024-04-10 Université de Montréal Biarylmethyl heterocycles
EA201991555A1 (ru) * 2016-12-22 2020-01-23 Мавуфарма, Инк. Композиции и способы усиления или увеличения продукции ifn i типа
KR20190126283A (ko) * 2016-12-22 2019-11-11 마브파마, 인크. 포스포디에스테라아제 저해제 및 미생물 치료 방법
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
EP3676254A4 (en) 2017-08-31 2021-01-13 AbbVie Inc. ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
KR20200066292A (ko) 2017-09-08 2020-06-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Enpp1 억제제 및 암의 치료를 위한 그의 용도
WO2019096113A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种氘代的含硼的化合物及药物组合物和用途
CN108409767B (zh) 2018-04-13 2020-07-10 上海泰坦科技股份有限公司 一种杂环联苯硼酸的制备方法
EP3902787A4 (en) 2018-12-28 2022-12-28 Riboscience LLC QUINAZOLINE DERIVATIVES USED AS ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 INHIBITORS
BR112021015098A2 (pt) 2019-02-01 2022-01-11 Univ Leland Stanford Junior Inibidores de enpp1 e métodos de modulação da resposta imune
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
BR112022004809A2 (pt) 2019-09-16 2022-06-21 Aten Porus Lifesciences Pvt Ltd Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1
EP4034094A4 (en) 2019-09-23 2024-01-24 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. PHOSPHODIESTERASE INHIBITORS AND THEIR USE
AU2020412779A1 (en) 2019-12-23 2022-06-23 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof
AR121269A1 (es) 2020-02-04 2022-05-04 Stingray Therapeutics Inc Inhibidores de la ectonucleótido pirofosfatasa / fosfodiesterasa 1 (enpp1) y métodos de uso de los mismos
CN115362150A (zh) 2020-04-09 2022-11-18 贝达药业股份有限公司 Enpp1抑制剂及其组合物和用途

Also Published As

Publication number Publication date
EP3952995A1 (en) 2022-02-16
HRP20231413T1 (hr) 2024-02-16
PT3952995T (pt) 2023-10-25
WO2020210649A1 (en) 2020-10-15
SG11202110888QA (en) 2021-10-28
EP3952995B1 (en) 2023-09-20
EP4249070A3 (en) 2024-04-17
CN114040915A (zh) 2022-02-11
SI3952995T1 (sl) 2023-12-29
DK3952995T3 (da) 2023-10-30
US12029744B2 (en) 2024-07-09
FI3952995T3 (fi) 2023-10-26
US20220362266A1 (en) 2022-11-17
PL3952995T3 (pl) 2024-03-11
HUE064377T2 (hu) 2024-03-28
JP2022526432A (ja) 2022-05-24
RS64792B1 (sr) 2023-11-30
ES2960987T3 (es) 2024-03-07
CA3136443A1 (en) 2020-10-15
AU2020272034A1 (en) 2021-10-28
MX2021012305A (es) 2021-11-12
BR112021020241A2 (pt) 2021-12-07
KR20210151873A (ko) 2021-12-14
TW202103708A (zh) 2021-02-01
EP4249070A2 (en) 2023-09-27
LT3952995T (lt) 2023-11-10
IL286966A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EP4327827A3 (en) Amorphous kinase inhibitor formulations and methods of use thereof
PH12020552207A1 (en) Pyrazole derivatives as malt1 inhibitors
MX2022013941A (es) Inhibidores de imino sulfanona de enpp1.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
MX2016006763A (es) Inhibidores de tirosina cinasa de bruton.
MX2016006744A (es) Inhibidores de tirosina cinasa de bruton.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2024002173A (es) Compuestos de arilsulfonilo como inhibidores de ccr6.